Talk about a quick dash after securing the money!
On Wednesday, pharmaceutical company Moderna announced that the CFO Jorge Gomez left after just one day of work, but he will still be collecting his full 12 months salary.
Prior to taking up his position at Moderna, Gomez served as Executive Vice President & Chief Financial Officer of Dentsply Sirona Inc. since August 2019.
“The announcement follows the public announcement on May 10 by Mr. Gomez’s former employer, Dentsply Sirona Inc., of an ongoing internal investigation into certain matters, including financial reporting,” Moderna said in a press release. company statement†
The internal investigation in question will determine whether or not the incentives used to help sell the dental supplier’s products to widespread distributors were “properly” accounted for. CNBC†
Gomez’s departure is effective immediately, with the company’s recently retired former CFO, David Meline, filling the position during the interim hiring process of a new candidate.
Related: Moderna shares spike after company says its Covid booster boosts antibody levels against Omicron
gomez was announced as Moderna’s new CFO on April 11, effective May 9.
“It is a privilege for me to join an organization focused on developing transformative medicines to address the major challenges in public health worldwide,” said Gomez. then† “I look forward to working with the team on this great mission.”
Gomez’ will still receive his $700,000 salary, although he will no longer be eligible for his signing bonus or future bonuses within the one-year period.
Denstsply board member and former Hillrom CEO John Groetelaars currently serves as interim CEO.
The news comes after the announcement by Dentsply CEO Don Casey was terminated from his position with the company on April 19 after four years, three weeks before the company announced its less-than-excellent Q1 2022 results.
“The first quarter was a challenging quarter and our financial performance and revised outlook reflect the impact of greater-than-expected macroeconomic headwinds and disappointing performance in the United States,” Interim CEO Groetelaars Shareholders told†
Moderna, on the other hand, had a exceptional first quartera tripling of Covid vaccine sales to an estimated $5.9 billion in revenue, sending shares skyrocketing more than 7% in Wednesday’s premarket trading.
Related: Moderna Says Vaccine Is 96% Effective In Teens